.

Defense Digest

Recent Florida PIP Appellate Decisions Put Focus Back on Swift and Automatic Medical Benefits Payments

Defense Digest, Vol. 28, No. 1, April 2022

April 1, 2022

by Sean P. Greenwalt

Key Points:

  • Florida’s Fourth District Court of Appeal has recently taken up two separate cases relating to the PIP litigation ancillary issues of interest and penalty and postage. 
  • In South Florida Pain & Rehabilitation of West Dade v. Infinity Auto Ins. Co., the court examined the question of whether a provider is entitled to attorney’s fees under § 627.736(8), Florida Statutes (2018), after having recovered a judgment solely on the statutory penalty and postage costs authorized by § 627.736(10). 
  • In Precision Diagnostic, Inc. v. Progressive Am. Ins. Co., the court answered whether the interest rate owed on a PIP claim should fluctuate quarterly or be paid based on the fixed quarter date the amount became overdue, and whether the doctrine of de minimis non curat lex is applicable to interest within the no-fault context.

It is promulgated that the purpose of Florida’s no-fault personal injury protection (PIP) statute is to ensure the “swift and virtually automatic payment” to the insured. Nunez v. Geico Gen. Ins. Co., 117 So.3d 388, 391 (Fla. 2013). However, PIP litigation has evolved over the years, and ancillary issues, such as the payment of penalty and postage reimbursement and various theories of interest calculation, began to develop, even in circumstances without no-fault benefits at issue. The result of a judgment for interest, penalty or postage alone in these instances would commonly result in an award of attorney’s fees and costs for plaintiffs. 

These ancillary issues involving interest, penalty and postage often evaded higher-level review until the January 1, 2021, statutory change to Florida’s appellate court jurisdiction, when most small claims and county court cases could be appealed directly to Florida’s District Courts of Appeal. Palmetto Physical Therapy Inc. v. Progressive Select Ins. Co., 320 So.3d 213 (Fla. 3d DCA 2021). As a result of the appellate jurisdiction change, within the last year, Florida’s Fourth District Court of Appeal has taken up two separate cases on the issues of interest and penalty and postage. Both decisions have focused on the purpose of Florida’s no-fault statute, which is to reimburse a claimant’s insurance benefits as a result of a motor vehicle accident. 

Penalty and postage reimbursements are essentially financial incentives for an insurer to pay PIP benefits correctly to avoid the pre-suit litigation phase entirely. Section 627.736(10)(d) reads: “[i]f, within 30 days after receipt of notice by the insurer, the overdue claim specified in the notice is paid by the insurer together with applicable interest and a penalty of 10 percent of the overdue amount paid by the insurer, subject to a maximum penalty of $250, no action may be brought against the insurer.” See also United Auto Ins. Co. v. 5-Star Rehabilitation Center, Inc., 2020 WL 6304285 (Fla. 11th Jud. Cir. App. 2020). The requirement for postal cost reimbursements is actually found separately in Section 627.736(10)(c).

In April 2021, the Fourth District Court of Appeal, in South Florida Pain & Rehabilitation of West Dade v. Infinity Auto Ins. Co., 318 So.3d 6 (Fla. 4th DCA 2021), took up the question of “whether [a] provider is entitled to attorney’s fees under section 627.736(8), Florida Statutes (2018), after it recovered a judgment solely on the statutory penalty and postage costs authorized by section 627.736(10)[.]” 

The court answered the question in the negative, citing to a plain language interpretation of the PIP statute. The court noted that an exception to section 627.736(8)’s entitlement to attorney’s fees occurs under “section 627.736(10)(d) [where] an insurer is not obligated to pay any attorney fees if it pays the insured’s PIP claim within thirty days after receipt of the pre-suit demand letter.” The Fourth District held that the absence of penalty and postage within the statute’s language controlled, finding: “[i]f the Legislature had intended for attorney’s fees to be otherwise recoverable under the statute, it would have said so.” 

Upon review of the totality of the opinion, it is evident that the importance of no-fault insurance is not ancillary issues or technicalities but the recovery of medical benefits to the actual plaintiffs. The court went on to clarify “[t]he Legislature’s intent when enacting the no-fault statute was to ensure the swift payment of ‘medical, surgical, funeral, and disability insurance benefits.’” 

While this particular opinion was limited to scenarios only involving penalty and postage, it appeared from the court’s judicial history concerning the recovery of attorney fees and costs that the same line of reasoning could potentially apply to the recovery of interest payments alone when no actual PIP benefits were at issue. To date, this has not occurred, but further opinions on interest have recently shaped the issue’s jurisprudence in the no-fault context. 

Later in the year, on October 20, 2021, the Fourth District Court of Appeal also issued two front opinions concerning interest. Interest as a legal issue in PIP has been well on its way to developing multiple legal theories, bolstering it as a matter almost as prevalent as recovering actual PIP benefits. Certain theories of recovery against interest stem from whether it was subject to the pre-suit demand requirement, if it must be specifically pled in a complaint, if the interest rate should change quarterly, or whether the doctrine of de minimis non curat lex to interest alone applied to the no-fault statute. 

Fla. Stat. Section 627.736(4)(d) provides the context for no-fault interest payments: 

All overdue payments bear simple interest at the rate established under s. 55.03 or the rate established in the insurance contract, whichever is greater for the quarter in which the payment became overdue, calculated from the date the insurer was furnished with written notice of the amount of covered loss. Interest is due at the time payment of the overdue claim is made.

The Fourth District Court of Appeal in Precision Diagnostic Inc. v. Progressive American Ins. Co., 330 So.3d 32 (Fla. 4th DCA 2021) took on two of the above issues in its interest decision. First, whether the interest rate owed on a PIP claim should fluctuate quarterly or be paid based on the fixed quarter date the amount became overdue, and second, whether the doctrine of de minimis non curat lex is applicable to interest within the no-fault context. 

As for the fluctuating interest issue, the court clarified a recently brewing interest argument by opining that interest should not be adjusted quarterly or left as to the specific quarter date that interest is due. Rather, interest should adjust based on the annually set rate. The court reasoned that, even though “the Chief Financial Officer sets the interest rate quarterly, section 55.03 [where PIP interest rates are taken from] only provides for an already established interest rate to adjust annually, not quarterly.” 

While the fluctuating interest decision will have far-reaching consequences much beyond the scope of this article, there will be an equally significant effect from the court’s recognition of the de minimis non curat lex doctrine to interest amounts in the no-fault context.

Black’s Law Dictionary defines the doctrine of de minimis non curat lex as “the law does not concern itself with trifles.” The Florida Supreme Court has described the legal maxim to mean that “the law does not care for small things.” Loeffler v. Roe, 69 So.2d 331, 338 (Fla. 1953). 

De minimis non curat lex “is a hallowed, long established and long recognized principle of law, and a party is entitled to call it in aid.” Precision Diagnostic, Inc., 330 So.3d at 35 (quoting Alec Samuels, De Minimis Non Curat Lex, 1985 Statute L. Rev. 167, 167 (1985)). Without the doctrine, litigation over trifling amounts will be a “waste of the time and money, and impair[] the dignity of the court and judge.” Id. (quoting Alec Samuels, De Minimis Non Curat Lex, 1985 Statute L. Rev. 167, 168 (1985)).  

In Precision Diagnostic, the provider sued over an interest difference of $4.17 based on the fluctuating interest argument above. When the trial court ruled in favor of the insurer’s de minimis argument, that the interest alone amount was too little to recover, the plaintiff’s appeal followed. The Fourth District Court of Appeal agreed with the insurer’s argument and noted the long history of the de minimis doctrine applying to a wide range of legal fields, including criminal, workers’ compensation and attorney fee awards for de minimis recoveries. However, the Precision Diagnostic decision is the first statewide binding appellate opinion explicitly recognizing the doctrine of de minimis non curat lex in the no-fault PIP context, although it is limited to interest-alone recoveries. 

A cause for concern for the Fourth District was the appearance that the case at issue was not brought for a genuine desire to recover $4.17 in miscalculated interest, “but rather for the award of attorney’s fees.” 

Time will tell the lasting effects of the above opinions. However, one common theme seems clear, the objective of Florida’s no-fault statute centers on the speedy reimbursement of medical, surgical, funeral and disability insurance benefits, not ancillary matters outside the core of the statute.

*Sean is an associate in our Tampa, Florida office. He may be reached at 813.989.1814 or spgreenwalt@mdwcg.com. 

 

Defense Digest, Vol. 28, No. 1, April 2022 is prepared by Marshall Dennehey Warner Coleman & Goggin to provide information on recent legal developments of interest to our readers. This publication is not intended to provide legal advice for a specific situation or to create an attorney-client relationship. ATTORNEY ADVERTISING pursuant to New York RPC 7.1. © 2022 Marshall Dennehey Warner Coleman & Goggin. All Rights Reserved. This article may not be reprinted without the express written permission of our firm. For reprints, contact tamontemuro@mdwcg.com.

Firm Highlights

Thought Leadership

SIDEBAR: News and Happenings

We are pleased to share that attorneys from our health care team have been selected to the 2026  New Jersey and Pennsylvania Super Lawyers and Rising Stars lists. Their dedication to clients and commitment to high-quality work continues to strengthen our firm! Please join us in congratulating: NJ Super Lawyers: Robert T. Evers and Justin F. Johnson NJ Super Lawyer Rising Stars: Nataliana A. Guida  2026 Pennsylvania Super Lawyers: Alyson J. Kirleis and Gary M. Samms 2026 Pennsylvania Rising Stars: Holli K. Archer and Daniel Dolente Victoria Scanlon (Scranton) was a faculty presenter at the 2026 American Roentgen Ray Society (ARRS) Annual Meeting in Pittsburgh. She participated in the “Resident Symposium: Producing Quality Reports,” focusing her presentation on “How to Write a Great Report: Malpractice Lawyer’s Perspective.” Vicky, the only attorney presenter for this two-hour segment, was joined by several health care professionals including diagnostic radiologists, an interventional radiologist, an internal medicine physician, and a radiologist turned AI entrepreneur expert.  Matthew Keris (Scranton), President of the Pennsylvania Association for Health Care Risk Management (PAHCRM) and shareholder in our Scranton Health Care Department, presented an important and timely session titled “Keynote Address: A Conversation with RaDonda Vaught on Criminalizing Errors” at PAHCRM’s Annual Meeting in April. RaDonda is a former Tennessee nurse widely known for being criminally convicted in 2022 of negligent homicide and gross neglect after a 2017 fatal medication error at Vanderbilt University Medical Center. Her case gained national attention because she was criminally prosecuted rather than just facing licensing board action, sparking debate over blaming individual nurses for systemic healthcare failures. Matt and RaDonda’s conversation explored one of the most consequential issues in health care risk management today—how systems respond to human error, and what it means for patient safety, accountability, and the professionals who serve on the front lines. Gary Samms was a panelist for a podcast hosted by the Medical Liability Monitor, “From Outliers to Pattern: The Increasing Predictability of Megaverdicts in the Med-Mal Industry – and How to Reduce the Likelihood of Getting Hit with One.” Gary discussed the changing megaverdict landscape and why “outlier” verdicts are becoming structural, in addition to how plaintiffs turn weaknesses into megaverdicts (including building emotional narrative and jury psychology). Thank you to our clients who joined us for our Trends in Health Care & Health Law seminar on May 14. Led by our Health Care Department Director and Assistant Director, Robin Snyder and Donna Modestine, the session explored key issues that are currently shaping outcomes in health care litigation. We owe a debt of gratitude to our esteemed guest speaker, Mary Ellen Nepps, Esq., Senior Counsel, University of Pennsylvania, who presented “Medical Malpractice Litigation: Driving Another Health Care Crisis in Pennsylvania.” And special thanks to our attorneys who presented and shared their insights, including John J. Hare and Holli Archer who discussed “Highlights in PA Medical Malpractice Law;” David Drake for his presentation, “From Claims to Courtroom: Key Trends in NJ Medical Malpractice Litigation;” and Matthew Keris with an “Update on Health Care Tech Discovery.” Thank you to all of our clients for entrusting us with your health care litigation. We are proud to partner with you as we defend your interests and navigate legal landscapes together.

Thought Leadership

Casual Care, Serious Consequences: How Informal Prescribing Can Trigger Medical Board Scrutiny

The lesson for health care practitioners is that regular review of the regulatory requirements can ensure compliance and that casual prescribing may be in violation of state regulations if the necessary components are not met. Consider the following scenario: in December 2025, a medical provider renewed a prescription for a long-standing telemedicine patient receiving a Schedule II controlled dangerous substance. This was not a violation of the New Jersey Administrative Code. Another provider doing the same action for an equally situated patient in March 2026 would be in violation. The casual prescriber who is not aware of newer regulatory requirements may have a more difficult time responding to a medical board complaint. Medicine is a highly-regulated helping profession. Without addressing the merits of this regulatory burden, the practice of medicine continues to see drastic changes impacting the everyday life of patient and provider. Telemedicine, COVID-19, and other advances and roadblocks, present a challenge to those saving lives while attempting to comply with the rules of practice. Physicians often discover—through real cases and the lens of regulatory expectations—that even well-intentioned informal help can be reinterpreted as stepping outside mandated professional boundaries, and seemingly harmless actions can be construed as deviations from required practice standards specifically outlined in Title 13, Chapter 35, Subchapters 7.1A of the New Jersey Administrative Code. Title 45, "Professions and Occupations," of the New Jersey code governs the practice of medicine, nursing, optometry, pharmacy, and many other professional occupations. Section 9 specifically addresses the state board of medical examiners and allows for the creation of rules and regulations in Section 45:9-5.3. These regulations can be found in the New Jersey Administrative Code Title 13, Chapter 35. While broad in scope, Chapter 35 contains a subchapter dedicated to the administration and dispensing of prescription drugs. Such knowledge will arm physicians with the tools they need to prevent a negative outcome if a medical board complaint is filed. Likewise, attorneys must be familiar with these regulatory requirements when advising and defending providers. In New Jersey, N.J.A.C. Section 13:35-7.1A(a) requires that a practitioner conduct an examination and appropriately document the same within the medical record before dispensing drugs or issuing prescriptions. The examination must include an "appropriate history and physical examination," a diagnosis based upon the examination and any testing consistent with good medical care, the formulation of a therapeutic plan discussed with the patient, and the availability of appropriate follow-up care. There are only six exceptions to this requirement: In admission orders for a newly hospitalized patient For a patient of another physician for whom the practitioner is taking calls For continuation medications on a short-term basis for a new patient prior to the patient's first appointment For an established patient who, based on sound medical practice, the physician believes does not require a new examination before issuing a new prescription For a patient examined by a healthcare professional who is in collaborative practice with the practitioner When treatment is provided by a practitioner for an emergency medical condition Emergencies are also limited to situations where someone's health is in serious jeopardy, there is serious impairment to bodily functions, or serious dysfunction of any bodily organ or part. During the COVID-19 pandemic, then New Jersey Governor Phil Murphy issued an executive order declaring a public health emergency and a state of emergency that allowed authorized prescribers to prescribe Schedule II controlled dangerous substances via telemedicine. The order was terminated when he left office earlier this year and the state reverted to the requirement of an initial in-person examination and quarterly in-person visits. With this return to prior regulatory requirements, practitioners subject to the jurisdiction of the board of medical examiners may benefit from a refresher on the regulatory limitations on their practice now that the pandemic-era flexibilities have ended. This new requirement may create confusion for prescribers and lead to casual prescribing of medication in violation of the regulations, even in the setting of recurrent telemedicine appointments as noted in the example above. Casual prescribing can take many forms: filling a prescription request from a friend or family member without an examination or contemporary medical record; using telemedicine to expand your practice without proper in-person appointments or documentation in the medical record; failing to ensure appropriate follow-up care for a "one time" prescription; etc. Although not all board complaints end in a publicly available opinion, serious deviations from regulatory requirements can shine a light on practices that will require action by the board if a complaint is received. Consider the following cases: In October 2025, the board issued a final consent order in an administrative action where a doctor provided opioids without examination and his license was permanently revoked. In re Robert Dela Gente, D.O., N.J. State Bd. of Med. Exam'rs Oct. 21, 2025. Criminal charges were filed (though that is not always the case). In a September 2025 consent order, a physician was reprimanded for "prescribing opioids several months in advance without the proper patient follow-up..." and explained that they did so for "patients who can not pay for multiple visits to refill medications." In re A/an E. Schultz, M.D., N.J. State Bd. of Med. Exam'rs Sept. 25, 2025. Another physician was suspended and placed on probation in a consent order for prescribing three patients the weight-loss medication "Ozempic" via text messages through a website called "Push Health" and without any further communication with the patients or taking a medical history. In re Laura E. Purdy, M.D., N.J. State Bd. of Med. Exam'rs Aug. 29, 2025. A June 2025 interim consent order required a "full evaluation and assessment of [a physician's] general knowledge and skill, with specific emphasis on his knowledge of and ability to safely prescribe [controlled dangerous substances]" due to his failure to review a patient's prior medical history and medical record, assess and review the prescription monitoring program before prescribing CDS, and conduct random urine screens on a patient that tested positive for CDS upon admission to his practice because "he trusted the patient." In re Donald Oh, M.D., N.J. State Bd. of Med. Exam'rs June 2, 2025. Each of these examples demonstrate a failure to follow strict procedure regardless of the intention. Failing to follow procedure secondary to good intentions, such as considering a patient's financial constraints, trust in the patient, or utilizing a new telemedicine service platform, will not be a defense to a board complaint. Especially when practicing via telemedicine, practitioners must ensure they are adhering to the appropriate regulatory standard. A provider who calls in a prescription for a traveling friend or family member or agrees to prescribe medication for individuals using the newest phone app will have a hard time meeting the requirements of N.J.A.C. Section 13:35-7.1A. Even if a history was taken, a "therapeutic plan" was created, and "follow up care" was provided, the prescriber would still not be in compliance with the regulation without an in-person examination. In our opening hypothetical, the prescriber's behavior did not change between December and March; however, the legal shift in the regulatory landscape made once acceptable behavior a violation as a required examination did not occur. When complaints are made with regard to informal prescribing, the board has discretion to employ measures to encourage compliance in lieu of formal proceedings such as a private, written warning; suspending fines subject to continuing compliance; medical or professional treatment as may be necessary; medical or diagnostic testing and monitoring; skills assessment; corrective training; participation in outreach programming; or contribution to the consumer fraud protection fund. The lesson for health care practitioners is that regular review of the regulatory requirements can ensure compliance and that casual prescribing may be in violation of state regulations if the necessary components are not met. Even compliant providers who had not conducted an in-person examination for telemedicine patients during the COVID-19 emergency would be in violation of the regulations as of January 2026 for the same practice. Practitioners should be diligent in adhering to the prescribing rules to avoid sanctions related to casual care. Likewise, attorneys advising or defending practitioners before the board must be aware of the in-person examination requirements for prescribing in New Jersey whether the care in question took place in-person or in a telemedicine setting. Reprinted with permission from the April 22, 2026 issue of the New Jersey Law Journal. ©2026 ALM Media Properties, LLC. Further duplication without permission is prohibited. All rights reserved.

Result

No-Cause Jury Verdict Secured in Wrongful Death Trial

We successfully obtained a no-cause jury verdict in a 13-day wrongful death trial. The decedent, a 59-year-old man, was admitted to the emergency room on February 15, 2019, with complaints of abdominal pain, decreased appetite, and constipation, despite the use of laxatives. The patient did not complain of any nausea, vomiting, or diarrhea. He had a significant medical history including diabetes, hypertension, prior coronary artery stenting, morbid obesity (with past gastric bypass surgery), longstanding ventral hernia, and back pain. A CT scan revealed multiple hernias and a potential closed-loop bowel obstruction, leading to a surgery consultation. Our client, an emergency general surgeon, interpreted that the patient did not have a closed loop or any significant obstruction and recommended non-surgical management. The patient was approved to have clear liquids, and had a vomiting incident shortly after, but our client was not notified. The patient was returned to NPO status, and after improving overnight, he was returned to “clears” and additional medical and renal consults were ordered. Our client did not receive any communications from the residents/nurses of any changes in the patient’s condition. On February 18, 2019, two rapid responses were called due to increased heart rate and vomiting. It is believed that the vomiting resulted in aspiration, causing sepsis, ultimately leading to the patient’s death. During the trial, the plaintiff’s sole medical expert highlighted imaging on the wrong hernia, which called into question all of his opinions in the case. We made key objections related to the expert testimony, limiting what the allegations were, and preventing new allegations from being made. After approximately two and a half hours of deliberating, the jury returned a no-cause verdict. 

News

Marshall Dennehey’s John J. Hare Brings Home Attorney of the Year Honors; Firm Named Litigation Department of the Year in Two Categories

Marshall Dennehey took home top honors in three categories at the The Legal Intelligencer’s 2026 Pennsylvania Legal Awards, held June 11 in Philadelphia. The first place awards include: Attorney of the Year: John J. Hare, Chair of the firm’s Appellate Advocacy & Post-Trial Practice Group and Executive Committee member, together with Charles “Chip” Becker of Kline & Specter Litigation Department of the Year, Appellate – Third Win in a Row! Litigation Department of the Year, Product Liability/Mass Torts “There is no one more deserving of Attorney of the Year honors than John. This award is a testament to his exceptional skill, dedication, and leadership—qualities that truly exemplify the very best of our firm,” said G. Mark Thompson, Marshall Dennehey’s President & CEO. “These honors also reflect the strength and depth of our product liability, mass torts, and appellate practices across Pennsylvania and beyond, underscoring our ongoing commitment to delivering outstanding results for our clients.” Attorney of the Year – John J. Hare, Marshall Dennehey, together with Charles “Chip” Becker, Kline & Specter Over the past year, John and Charles were opposing counsel in many of the highest-profile civil appeals in Pennsylvania. John is renowned as a preeminent appellate lawyer on the defense side, and Chip on the plaintiff's side. They have opposed each other repeatedly, exhibiting peerless professionalism and exceptional civility, while zealously litigating under the unremitting pressure of high-profile litigation and record-setting verdicts totaling more than $3.5 billion. They have also collaborated, outside of litigation, on many commissions, committees, and projects of importance to the Pennsylvania judiciary and legal community. Litigation Department of the Year – Appellate Law, Winner (previous winner, 2025 and 2024) 2025 was another standout year for the firm’s Appellate Advocacy & Post‑Trial Practice Group, led by John J. Hare, which was retained to challenge many of Pennsylvania’s “nuclear” verdicts—awards exceeding $10 million. Notably, the department persuaded the Pennsylvania Superior Court to reverse a Philadelphia judgment of $1.09 billion, the largest judgment ever overturned by a Pennsylvania appellate court. The group’s 11 full‑time Pennsylvania‑based appellate lawyers are at the center of Pennsylvania’s most high-profile matters, bringing more than 150 years of combined appellate experience. They routinely handle post‑trial and appellate matters and are frequently engaged to participate in and monitor trials in high‑exposure cases to ensure that critical legal issues are properly raised and preserved for appeal. Litigation Department of the Year – Product Liability/Mass Torts, Winner This marks the first win for the firm’s Pennsylvania Product Liability and Mass Torts practices, which operate within our Casualty Department, managed by Matthew Schorr and Jeff Rapattoni. For almost five decades, Fortune 500 product manufacturers/distributors and their insurers have turned to these groups to defend their litigation. Led by Bradley D. Remick and Vlada Tasich, our Product Liability group’s success can be attributed to its commitment to keeping abreast of ever-changing legal theories, judicial viewpoints, and evolving technology impacting the product liability landscape. Our attorneys have successfully handled thousands of product liability matters in all jurisdictions across the state. Likewise, our mass tort litigation practice – divided into Asbestos & Mass Tort, and Environmental & Toxic Tort Litigation –  has defended manufacturers, distributors, contractors, and premises owners in thousands of personal injury and other claims. Led by Kevin E. Hexstall and Patrick T. Reilly, most attorneys in these groups have more than 20 years of experience, and our seasoned trial team has tried hundreds of cases to verdict, consistently achieving strong results through both trials and settlements. In addition to these awards, Marshall Dennehey was a Litigation Department of the Year finalist for Professional Liability.